New research suggests that immunotherapy given before and after surgery could help patients with diffuse pleural mesothelioma, one of the most challenging cancers to treat. A phase II clinical trial tested immunotherapy in resectable cases, with promising results presented at the World Conference on Lung Cancer.
New research suggests that immunotherapy given before and after surgery could help patients with diffuse pleural mesothelioma, one of the most challenging cancers to treat. A phase II clinical trial tested immunotherapy in resectable cases, with promising results presented at the World Conference on Lung Cancer. New research suggests that immunotherapy given before and after surgery could help patients with diffuse pleural mesothelioma, one of the most challenging cancers to treat. A phase II clinical trial tested immunotherapy in resectable cases, with promising results presented at the World Conference on Lung Cancer.